ACM
CTMX icon

Aquilo Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Aquilo Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-101,767
Closed -$1.09M – 15
2019
Q1 		$1.09M Sell
101,767
-422,996
-81% -$6.25M 0.48% 14
2018
Q4 		$7.92M Sell
524,763
-150,000
-22% -$2.23M 3.84% 7
2018
Q3 		$12.5M Buy
674,763
+25,000
+4% +$570K 5.22% 7
2018
Q2 		$14.9M Buy
+649,763
New +$16.6M 12.25% 3

Other funds holding CTMX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Aquilo Capital Management's CTMX Position: Q2 2019 in Review

Aquilo Capital Management sold out of CytomX Therapeutics (CTMX) in Q2 2019, closing a stake of 101,767 shares — an estimated $1.09M sold.

Aquilo Capital Management first reported a position in CTMX in Q2 2018 and held it in 4 quarters. The position peaked at $14.9M in Q2 2018. 109 funds tracked by Wall St. Rank hold CTMX as of Q2 2019.

  • Aquilo Capital Management reported no remaining CytomX Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Aquilo Capital Management sold 101,767 CytomX Therapeutics shares in Q2 2019, an estimated $1.09M.
  • Aquilo Capital Management first reported a position in CytomX Therapeutics in Q2 2018 and held it in 4 quarters.
  • Aquilo Capital Management's CytomX Therapeutics position peaked at $14.9M in Q2 2018.
  • 109 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2019.

Based on Aquilo Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.